Top Markets
Coin of the day
Allgens Medical Technology Co. Ltd. Allgens Medical Technology Co. Ltd.

Allgens Medical Technology Co. Ltd.

688613
Kedudukan dalam Saham #16116
Allgens Medical Technology Co. Ltd. operates as a medical device firm,... Allgens Medical Technology Co. Ltd. operates as a medical device firm, concentrating on the development and production of sophisticated biomimetic synthetic bone graft systems. These innovative solutions are engineered for global deployment in areas where both cancellous (spongy) and cortical (dense outer layer) bone tissues have been compromised. The company's diverse product portfolio includes key offerings such as BonGold, a mineralized collagen scaffold designed for bone grafting procedures; the high-performance Alligator bone marrow aspirator; and OssaNova, a mineralized collagen-based material utilized for bone filling and augmentation. These products are broadly applied across a spectrum of orthopedic and skeletal repair interventions throughout the human anatomy. Allgens Medical Technology Co. Ltd. was established in 2004 and is headquartered in Beijing, China.
Harga Saham
$2.28
Modal Pasaran
$312.51M
Perubahan (1 hari)
0.70%
Perubahan (1 tahun)
-21.04%
Negara
CN
Perdagangan Allgens Medical Technology Co. Ltd. (688613)

Kategori

Hasil untuk Allgens Medical Technology Co. Ltd. (688613)
Hasil pada Sep 2026 TTM: 0
Menurut laporan kewangan terkini daripada Allgens Medical Technology Co. Ltd., hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Allgens Medical Technology Co. Ltd. dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
$46.59B -
US
$25.84B -
US
$35.48B -
IE
$21.00B -
US
$6.51B -
US